MCL Literature Feed

This case report describes a rare relapse of mantle cell lymphoma presenting as an isolated laryngeal mass, emphasizing the importance of considering unusual sites of recurrence in MCL patients.

This real-world database analysis shows MCL patients treated at academic centers had significantly longer overall survival and higher trial participation, highlighting a major care disparity versus community settings.

Real-world data from older Chinese MCL patients shows BTKi-based regimens and maintenance therapy significantly improve survival, validating these strategies for this specific, understudied elderly population.

In newly diagnosed MCL, higher total lymphocyte and B-cell counts in the bone marrow correlated with a lower percentage of disease progression, suggesting a potential prognostic flow cytometry biomarker.

Radiotherapy for localized orbital MCL achieves excellent long-term cancer-specific survival (83% at 15 years), supporting its use as a primary treatment, especially for elderly or frail patients.

This indirect treatment comparison provides the first comparative evidence between zanubrutinib and acalabrutinib for relapsed/refractory MCL, guiding clinical selection in the absence of a head-to-head trial.

This review summarizes the evolution of BTK inhibitors, from covalent to reversible agents, to overcome resistance and toxicity, highlighting their central role in current and future MCL therapies.

This first reported case of mantle cell lymphoma with hypereosinophilia demonstrates a rare paraneoplastic presentation where eosinophil counts normalized following successful immunochemotherapy, expanding the disease's clinical spectrum.

This case report identifies chronic enteroviral meningoencephalitis as a severe neurotoxicity of rituximab maintenance in MCL, demonstrating successful resolution with intravenous immunoglobulins (IVIg) and fluoxetine.

This review of BCL-2 inhibitors in other indolent lymphomas provides context for their use in MCL, summarizing preclinical and clinical data supporting this therapeutic class in B-cell malignancies.

This review summarizes preclinical nanocarrier strategies designed to improve ibrutinib's bioavailability and targeted delivery, potentially enhancing efficacy and reducing off-target toxicity for MCL patients in the future.

A systematic review finds MCL has particularly high uptake on CXCR4-targeted [68Ga]Ga-Pentixafor PET, suggesting its utility for staging and response assessment, potentially superior to FDG-PET.

This study confirms a rare DLBCL subtype with CCND1 rearrangement, molecularly distinct from MCL by its SOX11-negativity and DLBCL-like mutations, posing a critical diagnostic and therapeutic challenge.

In the frontline MANTLE-FIRST study, fitness status and time to first progression (PFS1) were identified as key prognostic factors for elderly MCL patients, impacting subsequent outcomes.

In the BRUIN study, relapsed/refractory MCL patients previously treated with a BTKi maintained or improved quality of life and symptoms on pirtobrutinib, supporting its favorable long-term tolerability.

Genomic analysis reveals MCL relapse is driven by pre-existing resistant clones from diagnosis, not new mutations, emphasizing the need for deep upfront responses to eradicate these subclones.

A preclinical multi-modal profiling platform integrating genomics, in vitro drug screening, and PDX models identified personalized therapies for BTKi-relapsed/refractory MCL, guiding treatment beyond single gene alterations.

Pirtobrutinib-tolerant MCL persister cells survive via a reversible TCA cycle metabolic switch, presenting a novel metabolic vulnerability to target and prevent drug resistance.

White-centered retinal hemorrhages (Roth spots) can be the initial presenting sign of an otherwise hidden mantle cell lymphoma, highlighting an important and unusual diagnostic clue for clinicians.

Blastoid or pleomorphic morphology in mantle cell lymphoma is associated with increased primary and acquired resistance to BTK inhibitors, identifying a high-risk population requiring alternative therapeutic strategies.

Optical Genome Mapping identified a rare IGL::CCND1 translocation in a CD23-positive case, revising a CLL diagnosis to MCL and demonstrating OGM's utility for detecting atypical presentations.

This report identifies KMT2A rearrangement as a rare genetic driver in MCL, defining a distinct subtype often associated with aggressive features like blastoid morphology and poor prognosis.

This large, real-world analysis confirms a dismal prognosis (median OS 5.4 months) for MCL patients progressing after CAR-T, establishing a benchmark for future trials in this high-risk population.

This review outlines emerging therapeutic strategies, such as bispecific antibodies and novel agents, for managing mantle cell lymphoma patients who have relapsed after CAR-T cell therapy.

This review explains how tumor microenvironment crosstalk with B-cell receptor signaling promotes MCL survival and BTKi resistance, underscoring the need to target these interactions for improved therapies.

This case report of mantle cell lymphoma presenting solely as a cutaneous nodule in an elderly patient underscores the need to consider lymphoma in atypical skin lesions for accurate diagnosis.

Integrating genomics and spatial proteomics defines three prognostic MCL subtypes, revealing high-risk TP53-mutated tumors are immune-infiltrated yet exhausted, highlighting potential therapeutic vulnerabilities.

A new immunocompetent mouse model co-expressing SOX11 and CCND1 faithfully recapitulates human MCL, providing a crucial platform for studying disease biology and testing novel immunotherapies.

This case report identifies mantle cell lymphoma as a rare cause of secondary thrombotic microangiopathy, diagnosed via kidney biopsy and resolved with chemotherapy, expanding the differential for this complication.

A case report of a TP53-deleted splenic marginal zone lymphoma acquiring a secondary CCND1 rearrangement upon high-grade transformation suggests an alternative pathway to cyclin D1-driven lymphomagenesis.